Study of a new pill for advanced tumors with high MSI
Part of Cancer clinical trials.
This trial tests an experimental pill (FS-207) for people with advanced solid tumors that have a specific genetic marker called MSI-H (high microsatellite instability) or dMMR. If you have already had immunotherapy that didn't work, this drug might help by attacking cancer cells in a new way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic solid tumor cancer that has grown or caused side effects after standard treatment.
- You have tried and failed an immunotherapy drug (checkpoint inhibitor).
- Your tumor must test positive for MSI-H or dMMR (high microsatellite instability or mismatch repair deficiency).
- You are in good enough health to be up and about (ECOG performance status 0-1) and expected to live at least 3 months.
- You have at least one measurable tumor (of a certain size on a CT or MRI scan).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called ASN-3186 for people with advanced solid tumors that haven't responded to standard treatments. The drug may work especially well if your cancer has certain DNA repair problems, like a BRCA mutation.
This trial tests a new drug called JMKX005425 for people with advanced solid tumors that have a specific genetic feature called MSI-H or dMMR. If you have this feature and your cancer has not responded to other treatments, this study may offer a new option.
This study tests a new experimental drug (called SYS6051) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find out if the drug is safe and how well it works, and it might help control your cancer.
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
This study tests a new drug (DS5361b) for people with advanced solid tumors that have high genetic instability (TMB-H or MSI-H). It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.